CardioVia's ViaOne technology includes a blunt-tip needle that remains concealed to help interventional cardiologists and electrophysiologists treat cardiac arrhythmias with a reduced risk of perforation or any other complications. 

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.

As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.

Christopher M. Kramer, MD, is a longtime cardiologist and cardiac imaging specialist. His one-year term as the head of the American College of Cardiology officially began at the end of ACC.25 in Chicago.

This week, Heart Rhythm Advocates announced its establishment and called on cardiologists and EPs to support its efforts with membership and joining committees to guide efforts.

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.